Stockscreener 앱 받기
1.67
2.34%
-0.04
시간 외 거래:
1.69
0.02
+1.20%
MAIA Biotechnology Inc 주식(MAIA)의 최신 뉴스
Is MAIA Biotechnology Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
What analysts say about MAIA Biotechnology Inc. stockGame-changing capital returns - jammulinksnews.com
MAIA Biotechnology Inc. Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com
MAIA Biotechnology’s 41% decline validates InvestingPro’s overvalued call By Investing.com - Investing.com
What drives MAIA Biotechnology Inc. stock priceExceptional earning trajectories - Autocar Professional
Is MAIA Biotechnology Inc. stock a growth or value playMomentum Swing Watchlist - beatles.ru
When is the best time to buy MAIA Biotechnology Inc. stockPro Trader Stock Focus - Newser
Maia Biotechnology stock soars after publishing promising preclinical data - Investing.com
MAIA Biotechnology Publishes Promising Preclinical Cancer Data - TipRanks
MAIA Biotechnology publishes preclinical data on cancer drug candidates By Investing.com - Investing.com Canada
Maia Biotechnology stock soars after publishing promising preclinical data By Investing.com - Investing.com Canada
MAIA Biotechnology publishes preclinical data on cancer drug candidates - Investing.com
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy - Business Wire
Why MAIA Biotechnology Inc. stock attracts strong analyst attentionFree Stock Selection - Newser
How MAIA Biotechnology Inc. stock performs during market volatilityFree Stock Investment Discussion Area - Newser
What makes MAIA Biotechnology Inc. stock price move sharplySteady Profit Stock Forecasts - Newser
MAIA Biotechnology doses first patient in expansion of Phase II lung cancer trial - Yahoo Finance
MAIA Biotechnology doses first patient in Taiwan for NSCLC trial By Investing.com - Investing.com South Africa
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer - BioSpace
MAIA Biotechnology Begins Phase 2 Trial Expansion - TipRanks
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Up 0.5% – Still a Buy? - Defense World
Public market insider buying at Canaccord Genuity Group (CF) - The Globe and Mail
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress - BioSpace
Maia Biotechnology enters stock purchase agreement for up to $587,905 with Prevail Partners - Investing.com
MAIA Biotechnology, Roche Partner for Hard-to-Treat Cancer Therapies - Contract Pharma
MAIA Biotechnology appoints HCC experts to scientific advisory board - Investing.com
MAIA Biotechnology, Roche sign supply agreement for cancer therapies - Yahoo Finance
MAIA Biotechnology partners with Roche for cancer treatment studies By Investing.com - Investing.com South Africa
Maia Biotechnology Signs Clinical Supply Deal With Roche; Shares Rise - MarketScreener
MAIA Biotech (MAIA) Partners with Roche for Cancer Treatment Study - GuruFocus
MAIA Biotechnology, Inc. Announces Master Clinical Supply Agreement with Roche for Hard-To-Treat Cancer Therapies - marketscreener.com
0.51%
자본화:
|
볼륨(24시간):